Sign up
Pharma Capital

Scancell Holdings extends collaboration with Sweden's Karolinska Institute

The company first teamed up with Sweden's world-leading medical research university two years ago
front of the karolina institute
The two are collaborating on a technology that hunts down cancer cells previously hidden from the immune system

Scancell Holdings Plc (LON:SCLP) shares rose on Thursday on news the firm has extended its collaboration with the rheumatology unit of the Karolinska Institute, Sweden’s world-leading medical research university.

The pair will focus on broadening the applications for Scancell’s Moditope platform, building on a relationship that’s been in place for more than two years.

READ: Scancell Holdings inks drug delivery technology deal

The Moditope technology is central to one of the company’s main drug candidates, MODI-1, which initially will be trialled in breast and ovarian cancer as well as sarcoma (tumours found in fat, muscle, bone and tendons).

The Scancell innovation acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.  

Scientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.

"We are pleased to have broadened our research collaboration with Professor Klareskog, Professor Malmström and their colleagues at the Karolinska Institute,” said Scancell’s chief scientific officer, Professor Lindy Durrant.

“Our research has shown that citrullinated proteins are involved in the control of tumour growth and we believe that this expanded collaboration will help us to   develop Moditope, not only for use in cancer vaccines but also as part of other cancer immunotherapy approaches."

In mid-morning trading, Scancell shares were 0.8% higher at 12.25p.

 -- Adds share price --

Ian_55ae0ddd437b7.jpg
Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.